Acquisition - October 1, 2019
AstraZeneca divests rights for Losec to Cheplapharm
AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm. The divestment includes medicines containing omeprazole marketed by AstraZeneca or its collaborators under the Acimax, Antra, Mepral, Mopral, Omepral and Zoltum medicine names. “This agreement forms part of our strategy of reducing the portfolio of mature medicines to enable […]
Acquisition - September 30, 2019
Sobi to acquire Dova Pharmaceuticals
Swedish Orphan Biovitrum (Sobi) has announced a definitive agreement to acquire Dova Pharmaceuticals by means of a tender offer. The transaction is valued at up to USD 915 million on a fully diluted basis The consideration consists of an upfront payment of USD 27.50 per share in cash and, one non-tradeable Contingent Value Right (CVR). […]
Acquisition - September 18, 2019
CellaVision to acquire RAL Diagnostics
The company has signed an agreement to acquire the French company RAL Diagnostics (RAL), which manufactures sample preparation products in hematology, pathology, cytology and microbiology. RAL’s sales in 2018 was about SEK 87 million and its EBITDA margin about 15 percent. The cash purchase price is SEK 268 million on a cash and debt-free basis. […]
Acquisition - September 16, 2019
Lundbeck to acquire Alder BioPharmaceuticals
Lundbeck and Alder BioPharmaceuticals have announced a definitive agreement for Lundbeck to acquire Alder in a transaction valued at up to USD 1.95 billion net of cash. Alder is a clinical-stage biopharmaceutical company committed to transforming migraine treatment through the discovery, development and commercialization of novel therapeutic antibodies. Through this acquisition, Lundbeck will continue to expand […]
Acquisition - August 29, 2019
Elekta makes strategic acquisition
Elekta has acquired ProKnow Systems in order to expand its offering of cloud-based solutions for advanced radiation therapy. With ProKnow’s products, such as ProKnow DS, Elekta’s customers will have access to high-quality, cloud-based, treatment planning analytics to standardize their practices, it states in its press release. ProKnow DS allows collective data from patient groups to […]
Acquisition - August 22, 2019
Cellink acquires the German company Cytena
The bioink company has entered an agreement with the owners of Cytena to acquire all its shares for a purchase price of 30.25M euros. Through cytena’s complementary technology offering, Cellink sees great synergies that will support future growth. About Cytena Cytena is a life science company focusing on single-cell technologies. It was founded in 2014 […]
